Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Cost-effectiveness of iptacopan for paroxysmal nocturnal hemoglobinuria

Satoko Ito, Karthik Chetlapalli, Daniel Wang, Kunal C Potnis, Rhys Richmond, Harlan Krumholz, Alfred I Lee, Adam Cuker, George Goshua

Blood blood.2024025176.

https://doi.org/10.1182/blood.2024025176

Published: 2024

Includes: Supplemental data

Journal Articles

Cost-effectiveness of prophylaxis with recombinant vs plasma-derived VWF in severe von Willebrand disease in the United States

Christina Waldron, Satoko Ito, Daniel Wang, Cecily Allen, Giri Viswanathan, Robert D. Bona, Adam Cuker, George Goshua

Blood (2024) 143 (22): 2332–2335.

https://doi.org/10.1182/blood.2024024209

Published: 2024

Includes: Supplemental data

Journal Articles

Cost-Effectiveness of Rapid Hemosil Versus in-House and Send-out ADAMTS13 Activity Testing in the Care of Patients with Immune Thrombotic Thrombocytopenic Purpura

Cecily Allen, Satoko Ito, Ayesha Butt, Adriana Purcell, Rhys Richmond, Adam Cuker, George Goshua

Blood (2023) 142 (Supplement 1): 368.

https://doi.org/10.1182/blood-2023-184927

Published: 2023

Journal Articles

Equitable Care for Severe Hemophilia_A: Distributional Cost-Effectiveness of Prophylactic Weekly Efanesoctocog Alfa Versus Standard-Care Factor VIII in Patients with Severe Hemophilia_A in the United States

Satoko Ito, Kunal C Potnis, Cecily Allen, Rhys Richmond, Christina Waldron, Giri Viswanathan, Robert D Bona, George Goshua

Blood (2023) 142 (Supplement 1): 492.

https://doi.org/10.1182/blood-2023-190420

Published: 2023

Journal Articles

Allotransplantation and Gene Therapy Equity for Children with Sickle Cell Disease: Distributional Cost-Effectiveness of Allotransplantation Vs Gene Therapy Vs Standard-of-Care in Pediatric Patients with Sickle Cell Disease in the United States

George Goshua, Satoko Ito, Karthik Chetlapalli, Kunal C Potnis, Cecelia Calhoun, Lakshmanan Krishnamurti, Harlan M. Krumholz, Ankur Pandya

Blood (2023) 142 (Supplement 1): 490.

https://doi.org/10.1182/blood-2023-191072

Published: 2023

Journal Articles

Cost-Effectiveness of Long-Term Prophylaxis with Plasma-Derived Vs. Recombinant Von Willebrand Factor in Severe Von Willebrand Disease

Christina Waldron, Satoko Ito, Daniel Wang, Cecily Allen, Giri Viswanathan, Robert D Bona, Adam Cuker, George Goshua

Blood (2023) 142 (Supplement 1): 3698.

https://doi.org/10.1182/blood-2023-188018

Published: 2023

Journal Articles

Longitudinal Systemic Bevacizumab Therapy Produces Cost Savings and Improves Quality-Adjusted Life Expectancy in the Care of Patients with Hereditary Hemorrhagic Telangiectasia with Moderate-to-Severe Bleeding

Daniel Wang, Satoko Ito, Christina Waldron, Ayesha Butt, Ellen Zhang, Harlan M. Krumholz, Hanny Al-Samkari, George Goshua

Blood (2023) 142 (Supplement 1): 2312.

https://doi.org/10.1182/blood-2023-185340

Published: 2023

Journal Articles

Cost-Effectiveness of Sutimlimab Versus Standard-of-Care in Transfusion Dependent Patients with Primary Cold Agglutinin Disease in the United States

Satoko Ito, Daniel Wang, Adriana Purcell, Karthik Chetlapalli, Alfred I Lee, Adam Cuker, George Goshua

Blood (2023) 142 (Supplement 1): 2316.

https://doi.org/10.1182/blood-2023-187270

Published: 2023

Journal Articles

Second-Line Therapy Sequencing in Primary Warm Autoimmune Hemolytic Anemia: Splenectomy-Rituximab Versus Rituximab-Splenectomy

Christina Waldron, Satoko Ito, Daniel Wang, Giri Viswanathan, Ayesha Butt, George Goshua

Blood (2023) 142 (Supplement 1): 2317.

https://doi.org/10.1182/blood-2023-189957

Published: 2023

Journal Articles

Setting Cost-Effective Price Thresholds before FDA Approval: Cost-Effectiveness of Iptacopan Monotherapy Versus Standard-of-Care Anti-C5 Therapy in Transfusion-Dependent, Treatment-Experienced Adult Patients with Paroxysmal Nocturnal Hemoglobinuria in the United States

Satoko Ito, Karthik Chetlapalli, Kunal C Potnis, Rhys Richmond, Daniel Wang, Alfred I Lee, George Goshua

Blood (2023) 142 (Supplement 1): 5042.

https://doi.org/10.1182/blood-2023-188063

Published: 2023

NARROW

Cost-effectiveness of iptacopan for paroxysmal nocturnal hemoglobinuria

Cost-effectiveness of prophylaxis with recombinant vs plasma-derived VWF in severe von Willebrand disease in the United States

Cost-Effectiveness of Rapid Hemosil Versus in-House and Send-out ADAMTS13 Activity Testing in the Care of Patients with Immune Thrombotic Thrombocytopenic Purpura

Equitable Care for Severe Hemophilia_A: Distributional Cost-Effectiveness of Prophylactic Weekly Efanesoctocog Alfa Versus Standard-Care Factor VIII in Patients with Severe Hemophilia_A in the United States

Allotransplantation and Gene Therapy Equity for Children with Sickle Cell Disease: Distributional Cost-Effectiveness of Allotransplantation Vs Gene Therapy Vs Standard-of-Care in Pediatric Patients with Sickle Cell Disease in the United States

Cost-Effectiveness of Long-Term Prophylaxis with Plasma-Derived Vs. Recombinant Von Willebrand Factor in Severe Von Willebrand Disease

Longitudinal Systemic Bevacizumab Therapy Produces Cost Savings and Improves Quality-Adjusted Life Expectancy in the Care of Patients with Hereditary Hemorrhagic Telangiectasia with Moderate-to-Severe Bleeding

Cost-Effectiveness of Sutimlimab Versus Standard-of-Care in Transfusion Dependent Patients with Primary Cold Agglutinin Disease in the United States

Second-Line Therapy Sequencing in Primary Warm Autoimmune Hemolytic Anemia: Splenectomy-Rituximab Versus Rituximab-Splenectomy

Setting Cost-Effective Price Thresholds before FDA Approval: Cost-Effectiveness of Iptacopan Monotherapy Versus Standard-of-Care Anti-C5 Therapy in Transfusion-Dependent, Treatment-Experienced Adult Patients with Paroxysmal Nocturnal Hemoglobinuria in the United States

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only